Neonatal Jaundice Case Study Ppt Template

1. Olusanya BO, Osibanjo FB, Slusher TM. (2015). Risk factors for severe neonatal hyperbilirubinemia in low and middle-income countries: a systematic review and meta-analysis. PLoS One, 10 (2): e0117229. [PMC free article][PubMed]

2. Bhutani VK, Zipursky A, Blencowe H, Khanna R, Sgro M, Ebbesen F. (2013). Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res, 1: 86–100. [PMC free article][PubMed]

3. American Academy of Pediatrics Practice Parameter (1994). Management of hyperbilirubinemia in the healthy term newborn. Pediatrics, 94: 558–65. [PubMed]

4. Burke BL, Robbins JM, Bird TM, Hobbs CA, Nesmith C, Tilford JM. (2009). Trends in hospitalizations for neonatal jaundice and kernicterus in the United States, 1988–2005. Pediatrics, 123: 524–32. [PubMed]

5. Young Infants Clinical Signs Study Group (2008). Clinical signs that predict severe illness in children under age 2 months: a multicentre study. Lancet, 371( 9607): 135–42. [PubMed]

6. Chou RH, Palmer RH, Ezhuthachan S, et al. (2003). Management of hyperbilirubinemia in newborns: measuring performance by using a benchmarking model. Pediatrics, 112: 1264–73. [PubMed]

7. Ogunfowora OB, Daniel OJ. (2006). Neonatal jaundice and its management: Knowledge, attitude and practice of community health workers in Nigeria. BMC Public Health, 6: 19. [PMC free article][PubMed]

8. Schneider AP. (1986). Breast milk jaundice in the newborn: A real entity. JAMA, 255( 23): 3270– 74. [PubMed]

9. Nag N, Halder S, Chaudhuri R, Adhikary S, Mazumder S. (2009). Role of bilirubin as antioxidant in neonatal jaundice and effect of ethanolic extract of sweet lime peel on experimentally induced jaundice in rat. Indian J Biochem Biophys, 46: 73–78. [PubMed]

10. Yousefi M, Rahimi H, Barikbin B, Toossi P, Lotfi S, Hedayati M, et al. (2011). Uric acid: a new antioxidant in patients with pemphigus vulgaris. IJD, 56( 3): 278–281. [PMC free article][PubMed]

11. Barikbin B, Yousefi M, Rahimi H, Hedayati M, Razavi SM, Lotfi S. (2011). Antioxidant status in patients with lichen planus. Clin Exp Dermatol, 36( 8): 851–54. [PubMed]

12. Paludetto R, Mansi G, Raimondi F, Romano A, Crivaro V, Bussi M, D’Ambrosio G. (2002). Moderate hyperbilirubinemia induces a transient alteration of neonatal behavior. Pediatrics, 110: e50. [PubMed]

13. Boo NY, Ishak S. (2007). Prediction of severe hyperbilirubinaemia using the Bilicheck transcutaneous bilirubinometer. J Paediatr Child Health, 43: 297–302. [PubMed]

14. Nass RD, Frank Y. (2010). Cognitive and Behavioral Abnormalities of Pediatric Diseases. 1st ed Oxford University Press.

15. Gartner LM, Lee KS. (1999). Jaundice in the breast-fed infant. Clin Perinatol, 26: 431–45. [PubMed]

16. Mesic I, Milas V, Medimurec M, Rimar Z. (2014). Unconjugated pathological jaundice in newborns. Coll Antropol, 38( 1): 173–8. [PubMed]

17. D’Silva S, Colah RB, Ghosh K, Mukherjee MB. (2014). Combined effects of the UGT1A1 and OATP2 gene polymorphisms as major risk factor for unconjugated hyperbilirubinemia in Indian neonates. Gene, 547( 1): 18–22. [PubMed]

18. Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW, Huang CS. (2004). Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res, 56( 5): 682–9. [PubMed]

19. Watchko JF, Lin Z. (2010). Exploring the genetic architecture of neonatal hyperbilirubinemia. Semin Fetal Neonatal Med, 15: 169–175. [PubMed]

20. Xu LY, He YJ, Zhang W, Deng S, Li Q, Zhang WX, et al. (2007). Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients. Acta Pharmacol Sin, 28: 1693–97. [PubMed]

21. Tirona RG, Leake BF, Merino G, and Kim RB. (2001). Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem, 276: 35669–35675. [PubMed]

22. Sanna S, Busonero F, Maschio A, McArdle PF, Usala G, Dei M, et al. (2009). Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet, 18: 2711–8. [PMC free article][PubMed]

23. Alencastro de Azevedo L, Reverbel da Silveira T, Carvalho CG, Martins de Castro S, Giugliani R, Matte U. (2012). UGT1A1, SLCO1B1, and SLCO1B3 polymorphisms vs. neonatal hyperbilirubinemia: is there an association?Pediatr Res, 72( 2): 169–73. [PubMed]

24. Mishra S, Agarwal R, Deorari AK, Paul VK. (2008). Jaundice in the newborns. Indian J Pediatr, 75( 2): 157–163. [PubMed]

25. Boyd S. (2004). Treatment of physiological and pathological neonatal jaundice. Nurs Times, 100( 13): 40–43. [PubMed]

26. Clarkson JE, Cowan JO, Herbison GP. (1984). Jaundice in full term healthy neonates: A population study. Aust Paediatr J, 20: 303–8. [PubMed]

27. Dennery PA, Seidman DS, Stevenson DK. (2001). Neonatal hyperbilirubinemia. NEJM, 344( 8): 581–290. [PubMed]

28. Maisels MJ, Gifford K. (1983). Neonatal jaundice in full-term infants. Role of breastfeeding and other causes. AJDC, 137: 561–2. [PubMed]

29. Alcock GS, Liley H. (2002). Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. CDSR, 3: CD003313. [PubMed]

30. Atkinson LR, Escobar GJ, Takyama JI, Newman TB. (2003). Phototherapy use in jaundiced newborns in a large managed care organization: do clinicians adhere to the guideline?Pediatrics, 111: e555–61. [PubMed]

31. Hansen TW. (2003). Recent advances in the pharmacotherapy for hyperbilirubinemia in the neonate. Expert Opin Pharmacother, 4( 11): 1939–1948. [PubMed]

32. Winfield CR, MacFaul R. (1978). Clinical study of prolonged jaundice in breast and bottle fed babies. Arch Dis Child, 53: 506–7. [PMC free article][PubMed]

33. Kramer LI. (1969). Advancement of dermal icterus in jaundiced newborn. AJDC, 118: 454–8. [PubMed]

34. Shapiro-Mendoza C. (2006). Risk factors for neonatal morbidity and mortality among “healthy” late preterm newborns. Semin Perinatol, 30: 54–60. [PubMed]

35. Dennery PA. (2002). Pharamacological interventions for the treatment of neonatal jaundice. Semin Neonatol, 7: 111–119. [PubMed]

36. Maruo Y, Nishizawa K, Sato H, Sawa H, Shimada M. (2000). Prolonged unconjugated hyperbilirubinemia associated with breast milk and mutations of the bilirubin uridine diphosphate- glucuronosyltransferase gene. Pediatrics, 106( 5): E59. [PubMed]

37. Maisels MJ. (1998). Jaundice. In: Taeugah H.W., Ballard R.A., Avery M.E., editors. (eds). Schaffers and Avery’s Diseases of Newborn ( 7th ed.). Philadelphia: WB Saunders Company; pp. 603– 708.

38. Al-Swaf FB, Jumaa RS, Saeed IS. (2009). Hemolytic disease of newborn due to ABO incompatibility. Tikrit Medical Journal, 15( 2): 70–78.

39. Stockman JA. (2001). Overview of the state of the art of Rh disease: history, current clinical management, and recent progress. J Pediatr Hematol Oncol, 23( 8): 554–62. [PubMed]

40. Bowman J. (2003). Thirty-five years of Rh prophylaxis. Transfusion, 43: 1661–6. [PubMed]

41. Van Kamp IL, Klumper FJ, Oepkes D, Meerman RH, Scherjon SA, Vandenbussche FP, et al. (2005). Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization. Am J Obstet Gynecol, 192( 1): 171–7. [PubMed]

42. Murray NA, Roberts IA. (2007). Haemolytic disease of the newborn. ADC Fetal Neonatal Ed, 92: 83–8. [PMC free article][PubMed]

43. Yigit S, Gursoy T, Kanra T, et al. (2005). Whole blood versus red cells and plasma for exchange transfusion in ABO haemolytic disease. Transfus Med, 15: 313–8. [PubMed]

44. Yaseen H, Khalaf M, Rashid N, Darwich M. (2005). Does prophylactic phototherapy prevent hyperbilirubinemia in neonates with ABO incompatibility and positive Coombs’ test?J Perinatol, 25: 590–4. [PubMed]

45. Kaplan M, Na’amad M, Kenan A, Rudensky B, Hammerman C, Vreman HJ, Wong RJ, Stevenson DK. (2009). Failure to predict hemolysis and hyperbilirubinemia by IgG subclass in blood group A or B infants born to group O mothers. Pediatrics, 123( 1): e132–7. [PubMed]

46. Moiz B, Nasir A, Khan SA, Kherani SA, Qadir M. (2012). Neonatal hyperbilirubinemia in infants with G6PD c.563C > T variant. BMC Pediatrics, 12: 126–133. [PMC free article][PubMed]

47. Marzban A, Mosavinasab N. (2008). Correlation between hemolysis and jaundice in Glucose 6-Phosphate Dehydrogenase deficient neonates. Acta Medica Iranica, 47( 5): 379–83.

48. Kaplan M, Hammerman C. (1998). Severe neonatal hyperbilirubinemia. A potential complication of glucose-6-phosphate dehydrogenase deficiency. Clin Perinatol, 25( 3): 575–90. [PubMed]

49. Bhutani VK, Johnson L, Sivieri ME. (1999). Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics, 103( 1): 6–16. [PubMed]

50. Cashore WJ. (2000). Bilirubin and jaundice in the micropremie. Clin Perinatol, 27: 171–9. [PubMed]

51. Johnson L, Bhutani VK. (1998). Guidelines for management of the jaundiced term and near term infant. Clin Perinatol, 25: 555–574. [PubMed]

52. Watson D, Rogers JA. (1961). A study of six representative methods of plasma bilirubin analysis. J Clin Pathol, 14: 271–8. [PMC free article][PubMed]

53. Yamanouchi I, Yamauchi Y, Igarashi I. (1980). Transcutaneous bilirubinometry: preliminary studies of noninvasive transcutaneous bilirubin meter in the Okayama National Hospital. Pediatrics, 65: 195–202. [PubMed]

54. Maisels MJ, Ostrea EM, Touch S, Clune SE, Cepeda E, Kring E, et al. (2004). Evaluation of a new transcutaneous bilirubinometer. Pediatrics, 113: 1628–35. [PubMed]

55. Gohmann K, Roser M, Rolinski B, Kadow I, Muller C, Goerlach-Graw A, et al. (2006). Bilirubin measurement for neonates: Comparison of 9 frequently used methods. Pediatrics, 117( 4): 1174–83. [PubMed]

56. Puppalwar PV, Goswami K, Dhok A. (2012). Review on “Evolution of Methods of Bilirubin Estimation”. IOSR-JDMS, 1( 3): 17–18.

57. Royal Prince Alfred Hospital (2003). Haemolytic jaundice, Rhesus isoimmunization. RPA Newborn care guidelines: Royal Prince Alfred Hospital, Sydney Australia.

58. Bosschaart N, Kok JH, Newsum AM, Ouwenee DM, Mentink R, van Leeuwen TG, et al. (2012). Limitations and opportunities of transcutaneous bilirubin measurement. Pediatrics, 129: 689–97. [PubMed]

59. Krishnasamy M, Bakri DR. (2009). Non-invasive, hand held transcutaneous bilirubinometer. Medical Development Division, Ministry of Health, Malaysia.

60. Robertson A, Kazmierczak S, Vos P. (2002). Improved transcutaneous bilirubinometry: comparison of SpectRx Bilicheck and Minolta jaundice meter JM-102 for estimating total serum in a normal newborn population. J Perinatolo, 22( 1): 12–14. [PubMed]

61. American Academy of Pediatrics (2004b). Clinical Practice Guideline: Subcommittee on Hyperbilirubinemia, Management of Hyperbilirubinemia in the newborn infant 35 or more week of gestation. Pediatrics, 114( 1): 297–316. [PubMed]

62. Watchko JF, Maisels MJ. (2003). Jaundice in low birth weight infants: pathobiology and outcome. Arch Dis Child Fetal Neonatal Ed, 88: F455–8. [PMC free article][PubMed]

63. Okwundu CI, Okoromah CAH, Shah PS. (2012). Prophylactic phototherapy for preventing jaundice in preterm or low birth weight infants. Cochrane Database Syst Rev, 2012(1): CD007966. [PubMed]

64. Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK. (2012). An approach to the management of hyperbilirubinemia in the preterm infant less than 35 week of gestation. J Perinatol, 32: 660–4. [PubMed]

65. Frank JE. (2005). Diagnosis and management of G6PD deficiency. Am Fam Physician, 72( 7): 1277–1282. [PubMed]

66. Engle WD, Jackson GL, Sendelbach D, Manning D, Frawley W. (2002). Assessment of a transcutaneous device in the evaluation of neonatal hyperbilirubinemia in a primarily Hispanic population. Pediatrics, 110: 61–67. [PubMed]

67. Schumacher R. (2002). Transcutaneous bilirubinometry and diagnostic tests: “the right job for the tool.”Pediatrics, 110: 407–408. [PubMed]

68. Ip S, Glicken S, Kulig J, Obrien R, Sege R, Lau J. (2003). Management of Neonatal Hyperbilirubinemia. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality. AHRQ Publication 03-E011.

69. Kappas A, Drummond GS, Munson DP, Marshall JR. (2001). Sn-mesoporphyrin interdiction of severe hyperbilirubinemia in Jehovah’s Witness newborns as an alternative to exchange transfusion. Pediatrics, 108: 1374–7. [PubMed]

70. Ennever JF. (1990). Blue light, green light, white light, more light: treatment of neonatal jaundice. Clin Perinatol, 17: 467–81. [PubMed]

71. Cremer RJ, Perryman RW, Richards DH. (1958). Influence of light on the hyperbilirubinaemia of infants. Lancet, 1: 1094–7. [PubMed]

72. Brown AK, Kim MH, Wu PY, Bryla DA. (1985). Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia. Pediatrics, 75: 393–400 [PubMed]

73. Vecchi C, Donzelli GP, Migliorini MG, Sbrana G. (1983). Green light in phototherapy. Pediatr Res, 17: 461–3. [PubMed]

74. Tan KL. (1989). Efficacy of fluorescent daylight, blue, and green lamps in the management of nonhemolytic hyperbilirubinemia. J Pediatr, 114: 132–7. [PubMed]

75. Tan KL. (1991). Phototherapy for neonatal jaundice. Clin Perinatol, 18: 423–39. [PubMed]

76. Amato M, Howald H, von Muralt G. (1985). Interruption of breast-feeding versus phototherapy as treatment of hyperbilirubinemia in full-term infants. Helvetica Paediatrica Acta, 40: 127–31. [PubMed]

77. Caldera R, Maynier M, Sender A, Brossard Y, Tortrat D, Galiay JC, Badoual J. (1993). The effect of human albumin in association with intensive phototherapy in the management of neonatal jaundice. Arch Fr Pediatr, 50: 399–402. [PubMed]

78. Maisels MJ. (2001). Phototherapy—traditional and nontraditional. J Perinatol, 21( suppl 1): S93–7. [PubMed]

79. Seidman DS, Moise J, Ergaz Z, Laor A, Vreman HJ, Stevenson DK, Gale R. (2000). A new blue light-emitting phototherapy device: A prospective randomized controlled study. J Pediatr, 136( 6): 771–4. [PubMed]

80. Harris M, Bernbaum J, Polin J, Zimmerman R, Polin RA. (2001). Developmental follow-up of breastfed term and near-term infants with marked hyperbilirubinemia. Pediatrics, 107: 1075–1080. [PubMed]

81. American Academy of Pediatrics (2004a). Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more week of gestation. Pediatrics, 114 ( 3): 297–316. [PubMed]

82. Royal Prince Alfred Hospital (2006). Transcuteneous bilirubinometers. RPA Newbon care guidelines, Royal Prince Alfred Hospital, Sydney Australia.

83. Hsia DYY, Allen FH, Gelliss SS, Drummond LK. (1952). Erythroblastosis fetalis, VIII: studies of serum bilirubin in relation to kernicterus. N Engl J Med, 247: 668–71. [PubMed]

84. Mollison PL, Cutbush M. (1954). Haemolytic disease of the newborn. In: Gairdner D, editor. , ed. Recent Advances in Pediatrics. New York, NY: P Blakiston & Son, pp: 110.

85. Gabilan JC. (1998). Pharmacologic treatment of neonatal jaundice. A new approach. Archives de Pediatrie, 5( 11): 1274–8. [PubMed]

86. Cuperus FJ, Hafkamp AM, Hulzebos CV, Verkade HJ. (2009). Pharmacological therapies for unconjugated hyperbilirubinemia. Curr Pharm Des, 15( 25): 2927–38.

Introduction

Newborn jaundice occurs in up to 85% of all live births.1–3 In the absence of haemolysis, sepsis, birth trauma or prematurity, it usually resolves within 3–5 days without significant complications.1 However, epidemiological evidence suggests that severe neonatal jaundice (SNJ) results in substantial morbidity and mortality.4 SNJ has been recognised as a significant cause of long-term neurocognitive and other sequelae, cerebral palsy, non-syndromic auditory neuropathy, deafness and learning difficulties.5 6 The burden is unacceptably high in low-income and middle-income countries (LMICs) and has prompted calls for intense scrutiny and attention.4 Under the millennium development goals, the potential impact of adverse perinatal conditions such as preterm birth complications and birth asphyxia on thriving and well-being beyond survival rarely received attention.7 With the current focus on inclusiveness for persons with disability under the sustainable development goals (SDGs), it is essential that we tackle SNJ as one key component of optimising neurodevelopmental outcome.7 8

A recent report by Bhutani et al4 noted that at least 481 000 term/near-term neonates are affected by SNJ/hyperbilirubinaemia each year, with 114 000 dying and an additional 63 000 surviving with kernicterus. However, these alarming estimates were based on limited data determined by mathematical modelling as true population-based data are limited and difficult to find. Therefore, the incidence of SNJ and thus its contribution to global neonatal morbidity and mortality presently remain unclear and possibly significantly underestimated.

Jaundice is usually recognised around a total serum bilirubin (TSB) of 5 mg/dL in neonates.3 SNJ is unlikely to happen before a TSB of at least 20–25 mg/dL in term neonates presenting early.4 TSB is unfortunately often either not available or delayed in many LMICs.9 Therefore, for the purposes of this article, severe SNJ is defined as jaundice associated with acute bilirubin encephalopathy (ABE)/kernicterus and/or exchange transfusions (ET) and/or jaundice-related death.

Phototherapy and ET are widely used therapeutic modalities for jaundice.2 However, due to constrained resources, devices for measuring bilirubin10 11 and effective phototherapy are often lacking in LMICs.12 This, together with higher prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency, blood group incompatibilities, late referrals and delayed recognition of excessive bilirubin levels in LMICs, has necessitated excessive use of ETs.13

We systematically reviewed the available evidence pertaining to the global burden of SNJ to inform child health policy regarding its prevention and management especially in LMICs.

Methods

Search criteria

Although most SNJ occurs at TSB at 20 mg/dL (343 µmol/L), there is no standard worldwide definition of SNJ or clinically significant TSB necessitating medical intervention. There is a wide range of definitions of significant jaundice. In studies reviewed in this article, TSB levels considered significant, when results were available, generally ranged from 15 to 30 mg/dL.14–27 Even though beginning in 2004, the American Academy of Pediatrics recommended ABE be used for acute manifestations of SNJ in the first weeks of life and kernicterus for chronic manifestations of SNJ/ABE,28 many still use the terms interchangeably. Because of limited availability of TSBs and our attempt to quantify the burden of clinical disease, we defined SNJ clinically using ABE, ET and jaundice-related death.

We systematically reviewed published papers following PRISMA guidelines (online supplementary appendix 1).13 Databases searched included Ovid Medline, PubMed, CINAHL, Global Health, Scopus, Popline, Africa Journal Online and Bioline databases for published articles on SNJ. We used both controlled subject headings and free-text terms for neonatal jaundice (NNJ), jaundice, bilirubin/blood levels, haemolytic anaemia, G6PD deficiency in various forms and in combination with terms for ET, ABE, kernicterus, death, mortality and phototherapy. Other inclusion criteria were jaundice in first month of life; availability of data on incidence of ABE/kernicterus; provision of information on incidence of ETs for SNJ or jaundice-related death which we defined as SNJ. We also reviewed references of selected retrieved articles and review papers, and contacted authors of relevant articles for missing dates. No language restrictions were used. To be included in the meta-analysis, a study must have reported estimates of incidence from a retrospective or prospective population-based study, increasing likelihood that estimates could be generalised to the geographical location where the study was conducted. The search results were limited to publication dates of 1990 to June 2017. See online supplementary appendix 2 for complete Ovid Medline search strategy.

Supplementary Material

Supplementary data

Data extraction

Two authors examined studies using a predetermined checklist (online supplementary appendix 3) devised by three authors for selecting articles that met inclusion criteria after one author screened titles and abstracts. Two authors independently confirmed eligibility of all full-text articles. Discrepancies were resolved by discussion and when needed by a third author. The following data were extracted from each article: publication year, study design, country, WHO region, sample size, SNJ definition and outcomes (ET, ABE, mortality). Articles were excluded if neonates were enrolled before 1990; study published after June 2017; sample size <10; ET unrelated to SNJ, results limited to only metabolic or primary liver diseases, studies with defined enrolment period, failure to define neonates as having ABE, ET or jaundice-related death and for the meta-analysis if they included only premature neonates.

Quality assessment

We explored several quality assessment tools reported in the literature for observational studies including the Newcastle-Ottawa Scale,29 and found none directly applicable for evaluating diagnostic studies on NNJ /hyperbilirubinaemia. We therefore chose to adopt the tool validated by Wong et al30 with all the critical components for assessing the risk of bias across studies. Two authors examined four important components of quality/risk of bias assessment: selection of subjects (representativeness), case definition for SNJ (exposure ascertainment), diagnostic criteria for jaundice and outcome measurement. Study quality was judged based on number of criteria that were met: all 4 (high), 2–3 (medium) or 1 (low). Finally, two authors determined which studies were population-based. We defined population-based studies as studies that addressed the incidence of SNJ for a defined population with every individual in the population having the same probability of being in the study and the results of the study having the ability to be generalisable to the whole population from which study participants were sampled and not necessarily the individuals included in the study.31 Disagreements were resolved through consensus after joint reassessment.

Statistical analysis

For the meta-analysis, when multiple reports were obtained from the same population with overlapping study years, the one providing sufficient data (ie, numerator and denominator data) to derive estimates of disease burden was selected. To facilitate meta-analytical techniques, estimates of incidence were logit transformed to enable them to correspond to probabilities under the standard normal and permit use of the normal distribution for significance testing. Pooled estimates were calculated using DerSimonian and Laird’s random effects method, weighting individual study estimates by the inverse of the variance of their transformed proportion as study weight, with their 95% (CI) determined using Clopper-Pearson exact binomial method.32 For presentation, pooled transformed estimates were back transformed. Statistical heterogeneity among studies was investigated using Cochran’s Q test and I2 with a conservative p value less than 0.1 chosen as the level of significance. Forest plots were then used to examine the overall effects. Exploration of potential sources of heterogeneity was undertaken using meta-regression. Whether it is an interventional or an observational study, small studies are more likely to show more extreme values given wider CIs compared with larger studies. Since more extreme findings may be more newsworthy and hence more likely to be published, potential for publication bias was assessed by visual inspection of the funnel plot as well as by formal means using Begg’s adjusted rank correlation and Egger’s regression asymmetry tests.33 All analyses were conducted using R Statistical Software.34

Results

Search of electronic databases identified 6844 articles (figure 1). Eight hundred and twenty papers were reviewed. After excluding studies not meeting inclusion criteria, 416 studies were selected for further review. Multiple languages (Chinese, English, Farsi, French, German, Hebrew, Italian, Norwegian, Polish, Portuguese, Serbian and Spanish) were represented, with translation of relevant sections, but only 26/416 were non-English, none of which were population based. Of these, 416 papers included at least one marker of SNJ, but only 21 provided population-based data on 4 975 406 neonates (table 1).

Figure 1

Flow chart of study selection for the meta‐analysis.

Sixteen (76%) were from high-income countries and 13 (62%) used a prospective study design. High-quality studies tended to report lower incidence compared with low-quality to moderate-quality studies (figure 2). High-quality studies tended to come from high-income countries with less disease while low-quality studies tend to come from LMICs. Overall, incidence estimates of SNJ from high-income countries tended to be lower compared with LMICs (figure 3). Studies which enrolled all neonates regardless of gestational age had a higher incidence of SNJ compared with studies enrolling only term/near-term (table 2).

Figure 2

Pooled incidence (per 10 000) of severe neonatal jaundice among all neonates aged 24 months or less according to study quality.

Figure 3

Pooled incidence (per 10 000) of severe neonatal jaundice among all neonates aged 24 months or less according to income.

The incidence of SNJ per 10 000 live births was highest in the African region at 667.8, followed by Southeast Asian at 251.3, Eastern Mediterranean with 165.7 and Western Pacific region with 9.4. The Americas and European regions each had substantially lower incidence of 4.4 and 3.2, respectively (table 3).

The incidence of ET per 10 000 live births was significantly higher for the African (186.5) and Southeast Asian (107.1) regions and lower in Eastern Mediterranean, Americas, European and Western Pacific regions reporting estimates of 17.8, 0.38, 0.35 and 0.19, respectively (table 4).

Visual inspection of funnel plot in which incidences of SNJ were plotted against their standard errors showed asymmetry. This was confirmed by formal tests of publication bias (Begg-Mazumdar test: p=0.016, Egger: bias, p=0.002). The observed heterogeneity between studies may explain the asymmetric funnel plots. In random effects meta-regression analyses, the overall observed between-study heterogeneity explained by covariates which were selected a priori (study design and duration, income classification of country and gestational age) was 66.23%; p<0.001. However, only income classification of country was statistically significant determinant of the incidence of SNJ (table 5). Only two  studies provided information on jaundice-related deaths with estimates of 2.8, 30.8 and 50.0 for UK (European),22 and India (Southeastern)35 While one study fromPakistan3 (Eastern Mediterranean), mentions death in 30% of infants with jaundice but stated they did not feel the deaths could be directly attributed to jaundice.

Table 1

Studies that met the inclusion criteria to be included in the meta-analysis

Table 2

Incidence (per 10 000 live births) of severe neonatal jaundice among all neonates aged 24 months or less by gestation and study design

Table 3

Incidence of severe neonatal jaundice per 10 000 live births, among all neonates aged 24 months or less

Table 4

Incidence of exchange transfusions, per 10 000 live births, among all neonates aged 24 months or less

Table 5

Meta-regression analysis potential factors* influencing the heterogeneity of incidence of severe neonatal jaundice

Discussion

Although data are limited despite our extensive literature review, this systematic review and meta-analysis suggests that the incidence of SNJ is high, with regions that include predominantly LMICs bearing the greatest burden of disease. In the systematic review, mentioned earlier by Bhutani et al4 18% of 134 million live births had SNJ with the greatest burden of disease in LMICs, and therefore supporting this hypothesis. But as previously pointed out, these estimates were generated by mathematical modelling due to lack of accurate incidence data available. Both Bhutani’s data as well as this review, highlight the glaring paucity of studies particularly in LMICs. Although all WHO regions are represented, only 4/136 (2.9%) LMICs countries were represented with most having only one study (India (Southeast) n=2,25 35 Nigeria (African) n=136 and Pakistan (Eastern Mediterranean) n=1,3 Vietnam (Western Pacific) n=1).37 In contrast representation among high-income countries, while low was better with 8/79 (10.1%) high-income countries having population-based data (Australia (Western Pacific) n=1,23 Canada (Americas) n=3,26 38 Denmark (European) n=3,15 17 39 Norway (European) n=1,24 Netherlands (European) n=1,20 Switzerland (European) n=1,27 USA (Americas) n=5,16 18 19 40 UK and Ireland (European) n=1).22 This general lack of population-based studies worldwide emphasises the need for more accurate data to determine the actual burden of disease.

Jaundice was the primary diagnosis in 17% of neonates ≤1 week in a hospital-based study in Kenya,41 and several other African-based studies demonstrate that SNJ commonly leads to hospital admissions.42–44 This pattern is also observed in Asia, including the Middle East.41 45–49

Although not readily generalisable, all regions do have numerous hospital-based studies among the 416 articles with at least one clinical indicator of SNJ, highlighting the prevalence of SNJ among admissions. For some countries, such as the USA and many European nations where hospital birth is the norm, this data would more accurately reflect true population-based data. However, in LMICs where ‘60 million women give birth outside a facility’ (2012)50 and recorded data population data spares, hospital data cannot be assumed to reflect true population data. The higher incidence of home births correlates well with the much higher incidence of SNJ noted in the studies from the African, Southeast Asian and Eastern Mediterranean regions compared with substantially lower incidence noted in the regions of the Americas and Europe.

Although only one study each from Africa and Eastern Mediterranean met the definition of population based, these two studies underscore the burden of ETs in LMIC’s with 186.5 and 107.1 ET’s per 10 000 live births in stark contrast to the American and European regions with only 0.38 and 0.35 per 10 000 live births, respectively.

ET for SNJ

While many paediatricians and even neonatologists in high-income countries never perform an ET, physicians in LMICs continue to perform ETs on a regular basis.13 Although population-based data were available in only a few LMICs studies, other hospital-based studies support their findings. Of note again is the high prevalence of ETs, reported in studies from many LMIC (22%–86%), particularly Nigeria,36 51 52 India53 54 and Bolivia.55

Access to ET, a proxy indicator of the magnitude of SNJ, is often limited in resource poor countries.13 56 57 Multiple studies have demonstrated early intervention including phototherapy and appropriate ET can prevent kernicterus.56 58 59 Despite benefits of ET, there are associated complications13 making it important to provide effective phototherapy before ET is needed.60

SNJ is significant due to the associated mortality, but some would argue even more so because of associated long-term morbidity especially in LMICs ill-equipped to handle these disabilities. Farouk et al reported abnormal neurological findings in almost 90% of infants returning for follow-up after ABE in their nursery.61 Olusanya and Somefun,62 reported ET as a risk factor for sensorineural hearing loss in their community-based study in Nigeria, as did da Silva et al in Brazil.63

Contribution of SNJ to neonatal mortality

While only two studies in this review,22 35 64 provided information on clear jaundice-related deaths, other studies have shown striking numbers of jaundice-related deaths where it reportedly accounted for 34% of neonatal deaths in Port Harcourt Nigeria,52 15% in Ile-Ife, Nigeria,65 14% in Kilifi District Kenya,66 6.7% in Cairo Egypt67 and 5.5% in Lagos Nigeria.68

Multiple factors contributing to kernicterus in LMICs and the need for solutions addressing these factors has been spelled out in articles by Olusanya et al69 and Slusher et al2 including the need for national guidelines,9 60 effective phototherapy, rapid reliable diagnostic tools, maternal and healthcare provider education.70

Contribution of SNJ to long-term disability

Current evidence indicates SNJ continues to contribute significantly to the burden of cerebral palsy, deafness and other auditory processing disorders.4 In India, Mukhopadhyay et al71 found an abnormal MRI or brainstem auditory evoked response in 61% and 76%, respectively, of children who underwent ET. In Nigeria, Ayanniyi and Abdulsalam72 reported NNJ as the leading cause of cerebral palsy (39.9%) trumping birth asphyxia (26.8%), while Ogunlesi et al73 also from Nigeria, reported cerebral palsy, seizure disorders and deafness as leading sequelae of ABE, occurring in 86.4%, 40.9% and 36.4%, respectively. Oztürk et al from Turkey,74 observed a history of prolonged jaundice commonly in children affected with cerebral palsy. Summing up available estimates, a recent Lancet article by Lawn et al75 indicts pathological hyperbilirubinaemia/jaundice in >114 000 deaths and states that there are >63 000 damaged survivors.

The increased global awareness of SNJ has led to improvement in some locations. One notable example of this is Myanmar where a package of services including a photoradiometer, education and intensive phototherapy decreased ET by 69%.76 Another example is the development, ongoing testing and refinement of filtered sunlight phototherapy in areas without access to continuous electricity or intensive phototherapy.77 Several studies have shown that maternal and health worker education, screening programmes14 18 28 38 and national guidelines78 can and do improve outcomes and decrease the observed clinical sequelae of SNJ.14 38 78 Many programmes supported by groups such as WHO79 and Essential Care for Every Baby80 now strongly support screening for jaundice and highlight it as a danger sign needing urgent care. This increased focus and awareness on SNJ is beginning to lead to decreases of this problem even in LMICs where recent studies though not always population based are beginning to show decreases in severe sequela.76

Some limitations of this comprehensive review should be noted, besides those inherent in meta-analysis.81 Only 12/195 sovereign nations82 are represented in the quantitative data. While highlighting one of the greatest problems in determining the actual burden of disease from SNJ, absence of data from other countries despite searching multiple databases limits generalisability of our findings. Another significant limitation is the marked variability in the actual focus of the articles. The populations studied, availability of a TSB, recommendations and methods of screening, differences in TSBs and many other variables of included articles span an extremely wide range. Finally, the initial search excluding articles by title was done by only one author and the auditory evoked brainstem response, which is rarely available in LMICs, where not included in the criteria for SNJ.

Despite these limitations, this review still fills critical holes in our knowledge about the true burden of disease from this devastating but preventable tragedy. To our knowledge, this is the first attempt to report the global burden of SNJ derived from population-based studies. While providing strong evidence for the burden of disease, it highlights the notable lack of population-based data from most countries, especially LMICs where the disease is more prevalent and most devastating. The burden of SNJ and its acute and chronic ramifications establish a strong case for appropriate health education, routine screening, early diagnosis and effective treatment. The spectrum of disease crosses ethnic and socioeconomic boundaries, impacting children everywhere, and is a commonly encountered hospital diagnosis worldwide. SNJ may represent the most common unrecognised and/or under-reported neonatal cause of preventable brain damage.83 More research with capacity building especially in LMICs and other areas where data are limited are needed to truly quantify the impact of this disease and to better understand how to integrate screening and therapy to eliminate this disease in the future.

Acknowledgments

We thank Dr Vinod Bhutani, Ms. Judith Hall RNC-NIC, and Dr Mark Ralston for their edits to an earlier version of the manuscript. We also thank Dr Philip Fischer, MD, Dr Reza Khodaverdian, Dr Janielle Nordell, Ms Ann Olthoff, RN, Dr Clydette Powell, Dr Hoda Pourhassan, Dr Maryam Sharifi-Sanjani, Ms Olja Šušilović, Dr Deborah Walker, Ms Allia Vaez and Ms Agnieszka Villanti, RN, for their help in the translation of foreign language literature used in this review. We also thank Ms Ayo Bode-Thomas, Dr Katie Durrwachter Erno, Mr Jeffrey Flores, Ms Judith Hall, RNC-NIC, Mr Jonathan Koffel, Ms Toni Okuyemi, Dr Mark Ralston, Mr Del Reed, Mr Paul Reid, Dr Yvonne Vaucher, Ms Mabel Wafula, Ms Katherine Warner, Dr Olga Steffens for their help in editing the article/tables including retrieving articles, verifying numbers, and managing Endnote.

References

  1. 1.↵
  2. 2.↵
  3. 3.↵
  4. 4.↵
  5. 5.↵
  6. 6.↵
  7. 7.↵
  8. 8.↵
  9. 9.↵
  10. 10.↵
  11. 11.↵

0 thoughts on “Neonatal Jaundice Case Study Ppt Template”

    -->

Leave a Comment

Your email address will not be published. Required fields are marked *